ICON Public (NASDAQ:ICLR) Releases FY 2021 Earnings Guidance

ICON Public (NASDAQ:ICLR) issued an update on its FY 2021 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $9.100-$9.500 for the period, compared to the Thomson Reuters consensus estimate of $8.710. The company issued revenue guidance of $5.30 billion-$5.50 billion, compared to the consensus revenue estimate of $3.69 billion.ICON Public also updated its FY21 guidance to $9.10-9.50 EPS.

Shares of ICLR stock traded down $4.55 during trading hours on Thursday, reaching $209.52. 8,041 shares of the company’s stock were exchanged, compared to its average volume of 1,494,241. The firm has a market cap of $11.23 billion, a P/E ratio of 33.16, a P/E/G ratio of 2.01 and a beta of 0.84. The business’s 50 day simple moving average is $218.10. ICON Public has a 1 year low of $168.76 and a 1 year high of $234.22. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.01 and a current ratio of 2.01.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Tuesday, July 20th. The medical research company reported $2.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.10 by $0.02. The business had revenue of $871.16 million during the quarter, compared to the consensus estimate of $857.30 million. ICON Public had a return on equity of 20.70% and a net margin of 11.49%. The company’s revenue for the quarter was up 40.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.20 EPS. Sell-side analysts forecast that ICON Public will post 9.16 EPS for the current fiscal year.

A number of equities research analysts recently weighed in on ICLR shares. Mizuho upped their price target on ICON Public from $217.00 to $242.00 and gave the stock a buy rating in a report on Monday, May 3rd. Bank of America started coverage on ICON Public in a report on Tuesday, April 13th. They issued a neutral rating on the stock. Jefferies Financial Group upped their price target on ICON Public from $256.00 to $267.00 and gave the stock a buy rating in a report on Thursday, April 29th. Wells Fargo & Company upgraded ICON Public from an equal weight rating to an overweight rating and upped their price target for the stock from $200.00 to $235.00 in a report on Thursday, April 1st. Finally, Citigroup started coverage on ICON Public in a report on Wednesday, July 14th. They issued a neutral rating and a $220.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $234.64.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

See Also: What can cause a stock to outperform?

Earnings History and Estimates for ICON Public (NASDAQ:ICLR)

Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.